New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.

Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional ...

These findings solidify the role of pembrolizumab as standard-of care for patients with previously untreated PD-L1-positive, advanced or metastatic NSCLC, according to investigators of the phase 3 ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

Pembrolizumab is also approved as first-line treatment in cisplatin-ineligible patients with high PD-L1 expression. 9 - 11 Integrating short courses of pre-RC immunotherapy in nonmetastatic MIBC has ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1), is currently marketed under the brand name Keytruda and is approved for 2 cervical cancer indications: ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

The addition of pemetrexed plus platinum chemotherapy to the immune checkpoint inhibitor pembrolizumab showed manageable toxicity among patients metastatic nonsquamous non-small cell lung cancer ...

More information: Quincy Chu et al, Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised ...

Findings showed that after a median follow-up of 25.6 months, pembrolizumab plus chemotherapy reduced the risk of death by 17% (hazard ratio, 0.83 [95% CI, 0.72-0.95]; P =.0034) compared with ...

Pembrolizumab currently has indications for certain types of melanoma, non—small-cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial cancer, microsatellite instability ...